Clinical data | |
---|---|
Trade names | Tridione |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration |
By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High |
Metabolism | Demethylated to dimethadione |
Biological half-life | 12–24 hours (trimethadione) 6–13 days (dimethadione) |
Excretion | Renal |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.004.406 |
Chemical and physical data | |
Formula | C6H9NO3 |
Molar mass | 143.141 g/mol |
3D model (JSmol) | |
|
|
|
|
Trimethadione is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments.
If administered during pregnancy, fetal trimethadione syndrome may result causing facial dysmorphism (short upturned nose, slanted eyebrows), cardiac defects, intrauterine growth restriction (IUGR), and mental retardation. The fetal loss rate while using trimethadione has been reported to be as high as 87%.